ProKidney (PROK) Competitors $0.77 -0.02 (-2.80%) Closing price 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.80%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, PRAX, and NRIXShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Ardelyx Zymeworks LENZ Therapeutics CureVac CorMedix Chimerix Avid Bioservices Cronos Group Praxis Precision Medicines Nurix Therapeutics ProKidney (NASDAQ:PROK) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation. Is PROK or ARDX more profitable? ProKidney has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. ProKidney's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Ardelyx -11.73%-24.87%-10.51% Does the MarketBeat Community believe in PROK or ARDX? Ardelyx received 531 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% ArdelyxOutperform Votes53967.46% Underperform Votes26032.54% Do analysts recommend PROK or ARDX? ProKidney presently has a consensus price target of $5.00, indicating a potential upside of 548.34%. Ardelyx has a consensus price target of $10.39, indicating a potential upside of 160.37%. Given ProKidney's higher probable upside, research analysts plainly believe ProKidney is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Ardelyx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has higher earnings and valuation, PROK or ARDX? ProKidney has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$306K737.68-$35.47M-$0.60-1.29Ardelyx$361.71M2.64-$39.14M-$0.22-18.14 Do institutionals and insiders hold more shares of PROK or ARDX? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 4.8% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, PROK or ARDX? ProKidney has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Does the media prefer PROK or ARDX? In the previous week, Ardelyx had 12 more articles in the media than ProKidney. MarketBeat recorded 12 mentions for Ardelyx and 0 mentions for ProKidney. Ardelyx's average media sentiment score of 0.85 beat ProKidney's score of -0.64 indicating that Ardelyx is being referred to more favorably in the news media. Company Overall Sentiment ProKidney Negative Ardelyx Positive SummaryArdelyx beats ProKidney on 10 of the 19 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.73M$2.93B$5.37B$8.38BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.4030.5026.8419.71Price / Sales737.68400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book-0.163.286.794.50Net Income-$35.47M-$72.17M$3.23B$248.18M7 Day Performance0.01%4.28%4.07%1.14%1 Month Performance5.23%7.62%12.52%15.20%1 Year Performance-79.16%-28.15%16.83%6.56% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney1.8089 of 5 stars$0.77-2.8%$5.00+548.3%-79.6%$225.73M$306,000.00-1.403ARDXArdelyx4.4986 of 5 stars$3.53-2.5%$10.39+194.3%-47.3%$844.57M$361.71M-22.0690Insider TradeZYMEZymeworks3.5197 of 5 stars$12.02+6.3%$21.00+74.7%+38.4%$836.32M$76.30M-8.01460News CoveragePositive NewsAnalyst ForecastInsider TradeLENZLENZ Therapeutics1.887 of 5 stars$29.37+11.5%$46.60+58.7%+54.5%$826.65MN/A-16.59110CVACCureVac3.7187 of 5 stars$3.62+4.3%$14.00+286.7%+25.9%$812.10M$535.18M6.58880News CoverageUpcoming EarningsGap DownCRMDCorMedix2.1004 of 5 stars$11.86+1.7%$15.00+26.5%+153.9%$804.40M$82.55M-14.6430Positive NewsCMRXChimerix0.5614 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.8126 of 5 stars$12.50+0.1%$12.25-2.0%+34.6%$799.18M$139.91M-5.23320High Trading VolumeCRONCronos Group1.015 of 5 stars$2.05+3.5%$3.50+70.7%-24.8%$790.08M$117.62M-15.77450Positive NewsHigh Trading VolumePRAXPraxis Precision Medicines3.1636 of 5 stars$38.42+0.2%$116.50+203.2%-11.8%$782.58M$8.12M-3.73110Positive NewsNRIXNurix Therapeutics2.4113 of 5 stars$10.18+7.2%$30.44+199.1%-37.4%$776.08M$56.42M-3.52300News CoveragePositive NewsGap Down Related Companies and Tools Related Companies ARDX Alternatives ZYME Alternatives LENZ Alternatives CVAC Alternatives CRMD Alternatives CMRX Alternatives CDMO Alternatives CRON Alternatives PRAX Alternatives NRIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
